<DOC>
	<DOCNO>NCT00251082</DOCNO>
	<brief_summary>To demonstrate efficacy continuous combine 0.5 mg estradiol 2.5 mg dydrogesterone versus placebo treatment vasomotor symptoms treatment period 3 month investigate bleeding pattern treatment period one year</brief_summary>
	<brief_title>Vasomotoric Symptoms Study 0.5 mg Estradiol 2.5 mg Dydrogesterone Combination</brief_title>
	<detailed_description />
	<mesh_term>Dydrogesterone</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Nonhysterectomised postmenopausal woman Amenorrhoea &gt; = 12 month Serum estradiol follicle stimulate hormone ( FSH ) postmenopausal range Known hypersensitivity estradiol , dydrogesterone excipients study medication Baseline endometrial biopsy result describe inclusion criterion ( endometrial tissue diagnosis , hyperplasia , carcinoma ) . Insufficient endometrial tissue diagnosis obtain baseline biopsy endometrial thickness &gt; = 5 mm ( double layer ) transvaginal ultrasound . The presence endometrial polyp baseline . Abnormal ( uninvestigated and/or unexplained ) vaginal bleed last 12 month prior Screening Visit ( Visit 1 ) . Estradiol pellet/implant therapy past 6 month . Previous systemic unopposed estrogen replacement therapy 6 month . History presence malignant neoplasms basal spinal cell carcinoma skin</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>hormone replacement</keyword>
	<keyword>vasomotoric symptom</keyword>
	<keyword>bleeding pattern</keyword>
</DOC>